EVALUATION OF THE EFFECTIVENESS OF QUERCETIN IN THE COMPLEX TREATMENT OF ACUTE MYOCARDIAL INFARCTION WITH ST SEGMENT ELEVATION

Abstract

The study examined the effect of cardioprotector, antioxidant, flavonoid quercetin on the clinical course and dynamics of the ST segment in patients with myocardial infarction with ST segment elevation. The study included 268 patients with acute myocardial infarction with ST segment elevation aged 20 to 69 years who were hospitalized in emergency departments No. 1 in the period from 2022 to 2023 on the basis of the Samarkand branch of the Republican scientific and Practical center for Emergency Medical Care. The patients were divided into 2 groups: group 1 – 132 patients with STEMI, to whom reperfusion was performed against the background of intravenous administration of quercetin; group 2 – 136 patients with STEMI, reperfusion was performed against the background of basic therapy. All patients underwent a general clinical examination (anamnesis collection, anthropometric and physical examination of the patient, measurement of blood pressure, heart rate). Laboratory and instrumental examination included clinical blood tests, biochemical blood analysis, examination of hemostasis indicators, upon admission and in dynamics on the 2nd and 7th day of admission, ECG, echocardiography, lung radiography, ultrasound according to indications. The addition of an intravenous form of quercetin in the complex therapy of STEMI improves the clinical course of the disease, accelerates the onset of reperfusion at the tissue level due to the cardioprotective properties of the drug, as evidenced by a rapid decrease in the ST segment.